Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China

被引:14
作者
Guo, Shui-Ming [1 ]
Han, Min [1 ]
Chen, Mei-Xue [1 ]
Ning, Yong [1 ]
Pei, Guang-Chang [1 ]
Li, Yue-Qiang [1 ]
Dai, Wei [1 ]
Ge, Shu-Wang [1 ]
Deng, Yuan-Jun [1 ]
Guo, Yan-Yan [1 ]
Li, Xiao-Qing [1 ]
Haller, Hermann [2 ]
Xu, Gang [1 ]
Rong, Song [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nephrol,Div Internal Med, Wuhan 430074, Hubei, Peoples R China
[2] Hannover Med Sch, Dept Nephrol, Hannover, Germany
基金
中国国家自然科学基金;
关键词
OXFORD CLASSIFICATION; GLOMERULAR-DISEASE; NATURAL-HISTORY; VALIDATION; SUPAR; ACTIVATION; EXPRESSION; PODOCYTES; FSGS;
D O I
10.1371/journal.pone.0138718
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Soluble urokinase receptor (suPAR) may be involved in the pathological mechanisms of focal segmental glomerulosclerosis (FSGS) changes. However, it remains unclear whether suPAR is correlated with the FSGS-like lesions in IgA nephropathy (IgAN). 3 Methods We measured the plasma suPAR levels in 138 patients with IgAN, and then their clinical and pathological relationships were analyzed. Results We found that the plasma suPAR levels were significantly correlated with age and renal function by both univariate and multivariate analysis in our IgAN patient cohort. Female had higher plasma suPAR levels and no significant correlation was observed between plasma suPAR levels and 24-h urine protein and highly sensitive C-reaction protein with multivariate analysis. In our cohort, sixty of these IgAN patients could be diagnosed with a type of FSGS lesions. The plasma suPAR levels were higher in the IgAN patients with FSGS lesions than in the IgAN patients without FSGS lesions by univariate (P < 0.0001) and multivariate (P < 0.001) analysis adjusting for other predictor variables, which might be helpful to differentiate the pathological changes with and without FSGS lesions. And the optimal cutoff value was 1806 pg/ml in this study. The plasma suPAR concentrations were also associated with the degree of tubular atrophy/interstitial fibrosis in both univariate and multivariate analysis. In multivariate analysis, the plasma suPAR levels were correlated with the percentage of crescents, not global sclerosis and arterial lesions. Conclusions Our study suggested that the plasma suPAR levels were associated with age, gender, renal function, the degree of tubular atrophy/interstitial fibrosis and the percentage of crescent formation. The plasma suPAR might be a potential predictor for the presence of FSGS pathological lesions in Chinese patients with IgAN.
引用
收藏
页数:15
相关论文
共 37 条
[1]  
[Anonymous], 1982, KIDNEY INT, V22, P643
[2]   uPAR: A versatile signalling orchestrator [J].
Blasi, F ;
Carmeliet, P .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (12) :932-943
[3]   The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification [J].
Cattran, Daniel C. ;
Coppo, Rosanna ;
Cook, H. Terence ;
Feehally, John ;
Roberts, Ian S. D. ;
Troyanov, Stephan ;
Alpers, Charles E. ;
Amore, Alessandro ;
Barratt, Jonathan ;
Berthoux, Francois ;
Bonsib, Stephen ;
Bruijn, Jan A. ;
D'Agati, Vivette ;
D'Amico, Giuseppe ;
Emancipator, Steven ;
Emma, Francesco ;
Ferrario, Franco ;
Fervenza, Fernando C. ;
Florquin, Sandrine ;
Fogo, Agnes ;
Geddes, Colin C. ;
Groene, Hermann-Josef ;
Haas, Mark ;
Herzenberg, Andrew M. ;
Hill, Prue A. ;
Hogg, Ronald J. ;
Hsu, Stephen I. ;
Jennette, J. Charles ;
Joh, Kensuke ;
Julian, Bruce A. ;
Kawamura, Tetsuya ;
Lai, Fernand M. ;
Leung, Chi Bon ;
Li, Lei-Shi ;
Li, Philip K. T. ;
Liu, Zhi-Hong ;
Mackinnon, Bruce ;
Mezzano, Sergio ;
Schena, F. Paolo ;
Tomino, Yasuhiko ;
Walker, Patrick D. ;
Wang, Haiyan ;
Weening, Jan J. ;
Yoshikawa, Nori ;
Zhang, Hong .
KIDNEY INTERNATIONAL, 2009, 76 (05) :534-545
[4]   Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments [J].
Coppo, Rosanna ;
Troyanov, Stephan ;
Bellur, Shubha ;
Cattran, Daniel ;
Cook, H. Terence ;
Feehally, John ;
Roberts, Ian S. D. ;
Morando, Laura ;
Camilla, Roberta ;
Tesar, Vladimir ;
Lunberg, Sigrid ;
Gesualdo, Loreto ;
Emma, Francesco ;
Rollino, Cristiana ;
Amore, Alessandro ;
Praga, Manuel ;
Feriozzi, Sandro ;
Segoloni, Giuseppe ;
Pani, Antonello ;
Cancarini, Giovanni ;
Durlik, Magalena ;
Moggia, Elisabetta ;
Mazzucco, Gianna ;
Giannakakis, Costantinos ;
Honsova, Eva ;
Sundelin, B. Brigitta ;
Di Palma, Anna Maria ;
Ferrario, Franco ;
Gutierrez, Eduardo ;
Asunis, Anna Maria ;
Barratt, Jonathan ;
Tardanico, Regina ;
Perkowska-Ptasinska, Agnieszka .
KIDNEY INTERNATIONAL, 2014, 86 (04) :828-836
[5]   Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes [J].
Coppo, Rosanna ;
Fonsato, Valentina ;
Balegno, Sabrina ;
Ricotti, Emanuela ;
Loiacono, Elisa ;
Camilla, Roberta ;
Peruzzi, Licia ;
Amore, Alessandro ;
Bussolati, Benedetta ;
Camussi, Giovanni .
KIDNEY INTERNATIONAL, 2010, 77 (05) :417-427
[6]   Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors [J].
D'Amico, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (02) :227-237
[7]   GLOMERULAR DISEASE The search goes on: suPAR is not the elusive FSGS factor [J].
Deegens, Jeroen K. ;
Wetzels, Jack E. .
NATURE REVIEWS NEPHROLOGY, 2014, 10 (08) :431-432
[8]   IgA nephropathy [J].
Donadio, JV ;
Grande, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (10) :738-748
[9]   Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies [J].
El Karoui, Khalil ;
Hill, Gary S. ;
Karras, Alexandre ;
Moulonguet, Luc ;
Caudwell, Valerie ;
Loupy, Alexandre ;
Bruneval, Patrick ;
Jacquot, Christian ;
Nochy, Dominique .
KIDNEY INTERNATIONAL, 2011, 79 (06) :643-654
[10]   Treatment of IgA nephropathy and Henoch-Schonlein nephritis [J].
Floege, Juergen ;
Feehally, John .
NATURE REVIEWS NEPHROLOGY, 2013, 9 (06) :320-327